Viaderma Inc
ViaDerma, Inc., through its subsidiary, manufactures and sells pharmaceutical related products in the United States. The company's lead product is Vitastem, a tetracycline and topical delivery technology for antibiotics to pain relief, skincare, and other. It is also developing various products for vitiligo, psoriasis, eczema, and other skin conditions using SkinPass topical delivery system, as w… Read more
Viaderma Inc (VDRM) - Total Liabilities
Latest total liabilities as of September 2024: $4.22 Million USD
Based on the latest financial reports, Viaderma Inc (VDRM) has total liabilities worth $4.22 Million USD as of September 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Viaderma Inc - Total Liabilities Trend (2008–2023)
This chart illustrates how Viaderma Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Viaderma Inc Competitors by Total Liabilities
The table below lists competitors of Viaderma Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Vista Land and Lifescapes Inc
PSE:VLL
|
Philippines | ₱215.11 Billion |
|
KLONDIKE SILVER
BE:K1SN
|
Germany | €4.36 Million |
|
Nusantara Inti Corpora Tbk
JK:UNIT
|
Indonesia | Rp116.65 Million |
|
H&G High Conviction Ltd
AU:HCF
|
Australia | AU$21.92K |
|
PLD CORPORATION
BE:P8O
|
Germany | €290.63K |
|
TIANJIN JINRAN -H-
BE:TL6
|
Germany | €747.66 Million |
Liability Composition Analysis (2008–2023)
This chart breaks down Viaderma Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.97 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -29.20 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.04 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Viaderma Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Viaderma Inc (2008–2023)
The table below shows the annual total liabilities of Viaderma Inc from 2008 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-12-31 | $1.16 Million | -54.75% |
| 2022-12-31 | $2.56 Million | -5.60% |
| 2021-12-31 | $2.71 Million | +17.28% |
| 2020-12-31 | $2.31 Million | -24.61% |
| 2019-12-31 | $3.07 Million | +10.39% |
| 2018-12-31 | $2.78 Million | +87.91% |
| 2017-12-31 | $1.48 Million | +119.46% |
| 2016-12-31 | $673.31K | -7.74% |
| 2015-12-31 | $729.76K | -21.89% |
| 2014-12-31 | $934.22K | -89.72% |
| 2011-12-31 | $9.09 Million | +32.31% |
| 2010-12-31 | $6.87 Million | +4.11% |
| 2009-12-31 | $6.60 Million | +34928.17% |
| 2008-12-31 | $18.83K | -- |